Sequencing of tumors and drugs targeted to mutations found in those cancers are beginning to change how cancer is treated, the Wall Street Journal reports.

The newspaper focuses on Kellie Carey, a lung cancer patient who was given a few months to live back in 2010. But through persistence, Carey persuaded her physicians to genotype her tumor, and they uncovered that she had an ALK gene mutation that could be targeted by Pfizer's Xalkori.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Between the Coasts

In a Name

Peace of Mind

The Pair of Them

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."